Medically refractory epilepsy remains a significant clinical challenge, affecting approximately 30 percent of the 3.4 million Americans living with epilepsy.
The FDA has approved Khindivi, the first hydrocortisone oral solution for pediatric adrenal insufficiency, offering precise, ready-to-use dosing for patients aged 5 years and older.
Innovations in craniosynostosis management and cranial vault remodeling have improved diagnosis, preoperative planning and treatment resulting in improved patient outcomes and more personalized care...